A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Placebo - Healthy ParticipantsDrug: ADEL-Y01 - healty participantsDrug: ADEL-Y01 - MCI/ADDrug: Placebo - MCI/AD
- Registration Number
- NCT06247345
- Lead Sponsor
- Alzheimer's Disease Expert Lab (ADEL), Inc.
- Brief Summary
This is a Phase Ia/Ib, two-part, randomized, placebo-controlled, double-blinded, first in human(FIH) study to evaluate the safety, tolerability, PK, and PD of ADEL-Y01 in healthy participants in Part 1 and participants with MCI due to AD and mild AD in Part 2. The study includes 2 parts: Part 1 (single ascending dose \[SAD\] and Part 2 (multiple ascending dose \[MAD\]).
- Detailed Description
The current standard of care (SoC) for Alzheimer's disease (AD) is aimed at improving memory and alertness only. There is an unmet medical need for an effective clinical treatment of neurodegeneration of AD and related dementia. Adel, Inc. and Oscotec Inc. are jointly developing a novel disease modifying immunotherapy agent (ADEL-Y01) targeting tubulin associated unit (tau) protein accumulation in the brain. ADEL-Y01 is a recombinant IgG1 class type monoclonal humanized antibody that recognizes and binds to tau protein acetylated at lysine-280 (K280) thus inhibiting aggregation and propagation of tau seeds and enhancing of microglial tau clearance. Administration of ADEL-Y01 has ameliorated memory impairment, behavioral deficits, and pathology in preclinical models. This first-in-human (FIH) study will assess the single and multiple dose safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) of ADEL-Y01 in healthy adult participants and participants with mild cognitive impairment (MCI) due to AD and mild AD.
Part 1 (SAD): Part 1 will recruit up to 40 healthy participants, age 18 to 65 years inclusive. Up to 5 cohorts of 8 participants (6 active and 2 placebo participants per cohort) will be enrolled with each participant receiving ADEL-Y01 or placebo. Participants will be screened within 28 days of dose administration. The participants who will meet the inclusion/exclusion criteria for the study will be enrolled into the study after providing the informed consent form (ICF). The eligible participants will be randomized on Day -1 to receive either single dose of ADEL-Y01 or placebo on Day 1. Participants will be admitted on Day -1 and remain in the clinical research unit for at least 4 days (Day 4) following completion of all schedule procedures. Participants will return to the clinical research unit for additional safety and PK assessments on 7 occasions over a total of 12-weeks. Each dose level will include 2 sentinel participants (1 active and 1 placebo) who will be dosed first and monitored by the Investigator for at least 24 hours to check safety and tolerability. Once the safety of the study intervention is ensured, remaining participants will be dosed (5 active and 1 placebo). The starting dose for the Part 1 (SAD) will be 2.5 mg/kg. Subsequent dose levels are tentatively assigned to be 7.5, 20, 50 and 100 mg/kg. Dose escalation to the next dose level(s) will not proceed until the safety and tolerability of ADEL-Y01 results over an at least 14-day assessment period have been evaluated by the Safety Review Committee (SRC). A randomization list will be prepared for each cohort separately. No participant will be dosed more than once.
Part 2 (MAD): Part 2 will evaluate multiple IV doses of ADEL-Y01 administered every 2 weeks (Q2W) for 12 weeks in participants with MCI due to AD or mild AD. Thirty-three participants aged 50 to 80 years will be enrolled into 3 cohorts of 11 participants per cohort (8 active, 3 placebo) with each participant assigned to receive 6 doses of either ADEL-Y01 or placebo. Participants will be screened within 28 days of dose administration. The participants who will meet the inclusion/exclusion criteria for the study will be enrolled into the study after providing the ICF. The eligible participants will be randomized on Day -1 to receive either single dose of ADEL-Y01 or placebo on Day 1. Participants will be admitted on Day -1 and remain in the clinical research unit for at least 24 hours post infusion (Day 2) following completion of all schedule procedures. Participants will return to the clinical research unit for ADEL-Y01/placebo administration and/or additional safety and PK assessments on 12 occasions over a total of up to 22 weeks (ie, 12-weeks relative to the administration of the last dose of study intervention scheduled on Day 71). The provisional doses planned in Part 2 (MAD) are 7.5, 20, and 50 mg/kg administered every 2 weeks. The starting dose for the MAD part will be based on both safety and PK results from the Part 1 (SAD). The starting dose will be selected so that anticipated repeated-dose exposure to ADEL-Y01 (Cmax and AUC) does not exceed the exposure at the highest dose determined to be safe and well tolerated in the SAD. Depending on the Q2W ADEL-Y01 dose selected, the Part 2 (MAD) may commence prior to completion of the SAD study part. Dose escalation to the next dose level(s) will not proceed until the safety and tolerability of ADEL-Y01 over an at least 6-week assessment period (3 doses) have been evaluated by the SRC.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 73
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description SAD Cohort 1: Placebo at a dose of 2.5mg/Kg Placebo - Healthy Participants This arm represents the group receiving placebo at a dose of 2.5mg/Kg in SAD cohort 1. SAD Cohort 2: ADEL Y-01 antibody at a dose of 7.5mg/Kg ADEL-Y01 - healty participants This arm represents the group receiving ADEL Y-01 antibody at a dose of 7.5 mg/Kg in SAD cohort 2. SAD Cohort 3: ADEL Y-01 antibody at a dose of 20mg/Kg ADEL-Y01 - healty participants This arm represents the group receiving ADEL Y-01 antibody at a dose of 20mg/Kg in SAD cohort 3. SAD Cohort 4: ADEL Y-01 antibody at a dose of 50mg/Kg ADEL-Y01 - healty participants This arm represents the group receiving ADEL Y-01 antibody at a dose of 50mg/Kg in SAD cohort 4. SAD Cohort 5: ADEL Y-01 antibody at a dose of 100mg/Kg ADEL-Y01 - healty participants This arm represents the group receiving ADEL Y-01 antibody at a dose of 100mg/Kg in SAD cohort 5. SAD Cohort 1: ADEL Y-01 antibody at a dose of 2.5mg/Kg ADEL-Y01 - healty participants This arm represents the group receiving ADEL Y-01 antibody at a dose of 2.5mg/Kg in SAD cohort 1. SAD Cohort 2: Placebo at a dose of 7.5mg/Kg Placebo - Healthy Participants This arm represents the group receiving placebo at a dose of 7.5mg/Kg in SAD cohort 2. SAD Cohort 3: Placebo at a dose of 20mg/Kg Placebo - Healthy Participants This arm represents the group receiving placebo at a dose of 20mg/Kg in SAD cohort 3. MAD Cohort 3: ADEL Y-01 antibody at a dose of 50mg/Kg ADEL-Y01 - MCI/AD This arm represents the group receiving ADEL Y-01 antibody at a dose of 50mg/Kg in MAD cohort 3. SAD Cohort 4: Placebo at a dose of 50mg/Kg Placebo - Healthy Participants This arm represents the group receiving placebo at a dose of 50mg/Kg in SAD cohort 4. SAD Cohort 5: Placebo at a dose of 100mg/Kg Placebo - Healthy Participants This arm represents the group receiving placebo at a dose of 100mg/Kg in SAD cohort 5. MAD Cohort 1: Placebo at a dose of 7.5mg/Kg Placebo - MCI/AD This arm represents the group receiving placebo at a dose of 7.5mg/Kg in MAD cohort 1. MAD Cohort 1: ADEL Y-01 antibody at a dose of 7.5mg/Kg ADEL-Y01 - MCI/AD This arm represents the group receiving ADEL Y-01 antibody at a dose of 7.5 mg/Kg in MAD cohort 1. MAD Cohort 2: ADEL Y-01 antibody at a dose of 20mg/Kg ADEL-Y01 - MCI/AD This arm represents the group receiving ADEL Y-01 antibody at a dose of 20mg/Kg in MAD cohort 2. MAD Cohort 2: Placebo at a dose of 20mg/Kg Placebo - MCI/AD This arm represents the group receiving placebo at a dose of 20mg/Kg in MAD cohort 2. MAD Cohort 3: Placebo at a dose of 50mg/Kg Placebo - MCI/AD This arm represents the group receiving placebo at a dose of 50mg/Kg in MAD cohort 3.
- Primary Outcome Measures
Name Time Method Part 2: Assessment of safety and tolerability with multiple IV Administrations of ADEL-Y01 in participants with MCI due to AD or Mild AD D-28 ~ Week 22 The study will assess standard safety and tolerability parameters, including but not limited to the following:
Adverse Events (AEs) Vital signs such as blood pressure, pulse rate, pulse oximetry, respiratory rate, and body temperature Digital 12-lead ECGs Clinical laboratory assessments, including Hematology, Biochemistry, Coagulation, and Urinalysis Physical examinations, which will encompass neurological assessments C-SSRS (Columbia-Suicide Severity Rating Scale) assessments.Part 1: Evaluation of the safety and tolerability of ADEL-Y01 via single IV injection D-28 ~ Week 12 The standard safety and tolerability parameters to be assessed in the study include, but are not limited to, the following:
Adverse Events (AEs) Vital signs, including blood pressure, pulse rate, pulse oximetry, respiratory rate, and body temperature Digital 12-lead ECGs Clinical laboratory assessments, encompassing hematology, biochemistry, coagulation, and urinalysis Physical examinations, which will include neurological assessments.
- Secondary Outcome Measures
Name Time Method Part 1: Characterization of the pharmacokinetics of ADEL-Y01 following a single IV injection D-28 ~ Week 12 The parameters and assessments in the study include serum Cmax, CEOI, tmax, AUC(0-last), AUC(0-inf), t1/2, λz, CL, Vss, Vz, as well as the incidence of anti-ADEL-Y01 antibodies in serum, ADEL-Y01 concentration at two specified time points (Day 2 and Day 15) in at least one cohort (20 mg/kg), and CSF to serum concentration ratios.
Part 1: Assessment of the exposure to ADEL-Y01 in CSF following a single IV injection D-28 ~ Week 12 The parameters and assessments in the study include serum Cmax, CEOI, tmax, AUC(0-last), AUC(0-inf), t1/2, λz, CL, Vss, Vz, as well as the incidence of anti-ADEL-Y01 antibodies in serum, ADEL-Y01 concentration at two specified time points (Day 2 and Day 15) in at least one cohort (20 mg/kg), and CSF to serum concentration ratios.
Part 2: Characterization of the pharmacokinetics of ADEL-Y01 in participants with MCI due to AD and mild AD following multiple IV injections D-28 ~ Week 22 Assessing serum Cmax, tmax, AUC(0-last), AUC(0-tau), t1/2, CL, Vss, Vz, accumulation, and serum trough concentrations.
Monitoring the incidence of anti-ADEL-Y01 antibodies in serum.
Measuring CSF ADEL-Y01 concentration at two specified time points (1 day and 14 days after the final dose) from all cohorts, including CSF to serum concentration ratios.
Evaluating changes in global function from baseline using the CDR-SB (Clinical Dementia Rating Scale Sum of Boxes) in participants with Alzheimer's disease.
Assessing changes in cognitive function from baseline using the MMSE (Mini-Mental State Examination) in participants with Alzheimer's disease.Part 1: Assessment of the immunogenicity of ADEL-Y01 following a single IV injection D-28 ~ Week 12 The parameters and assessments in the study include serum Cmax, CEOI, tmax, AUC(0-last), AUC(0-inf), t1/2, λz, CL, Vss, Vz, as well as the incidence of anti-ADEL-Y01 antibodies in serum, ADEL-Y01 concentration at two specified time points (Day 2 and Day 15) in at least one cohort (20 mg/kg), and CSF to serum concentration ratios.
Part 2: Assessment of the exposure to ADEL-Y01 in CSF in participants with MCI due to AD and mild AD following multiple IV injections. D-28 ~ Week 22 Assessing serum Cmax, tmax, AUC(0-last), AUC(0-tau), t1/2, CL, Vss, Vz, accumulation, and serum trough concentrations.
Monitoring the incidence of anti-ADEL-Y01 antibodies in serum.
Measuring CSF ADEL-Y01 concentration at two specified time points (1 day and 14 days after the final dose) from all cohorts, including CSF to serum concentration ratios.
Evaluating changes in global function from baseline using the CDR-SB (Clinical Dementia Rating Scale Sum of Boxes) in participants with Alzheimer's disease.
Assessing changes in cognitive function from baseline using the MMSE (Mini-Mental State Examination) in participants with Alzheimer's disease.Part 2: Assessment of the immunogenicity of ADEL-Y01 in participants with MCI due to AD and mild AD following multiple IV injections D-28 ~ Week 22 Assessing serum Cmax, tmax, AUC(0-last), AUC(0-tau), t1/2, CL, Vss, Vz, accumulation, and serum trough concentrations.
Monitoring the incidence of anti-ADEL-Y01 antibodies in serum.
Measuring CSF ADEL-Y01 concentration at two specified time points (1 day and 14 days after the final dose) from all cohorts, including CSF to serum concentration ratios.
Evaluating changes in global function from baseline using the CDR-SB (Clinical Dementia Rating Scale Sum of Boxes) in participants with Alzheimer's disease.
Assessing changes in cognitive function from baseline using the MMSE (Mini-Mental State Examination) in participants with Alzheimer's disease.Part 2: Assessment of the preliminary clinical activity of ADEL-Y01 in participants with MCI due to AD and mild AD following multiple IV injections. D-28 ~ Week 22 Assessing serum Cmax, tmax, AUC(0-last), AUC(0-tau), t1/2, CL, Vss, Vz, accumulation, and serum trough concentrations.
Monitoring the incidence of anti-ADEL-Y01 antibodies in serum.
Measuring CSF ADEL-Y01 concentration at two specified time points (1 day and 14 days after the final dose) from all cohorts, including CSF to serum concentration ratios.
Evaluating changes in global function from baseline using the CDR-SB (Clinical Dementia Rating Scale Sum of Boxes) in participants with Alzheimer's disease.
Assessing changes in cognitive function from baseline using the MMSE (Mini-Mental State Examination) in participants with Alzheimer's disease.
Trial Locations
- Locations (4)
Innovation Medical Research
🇺🇸Palmetto Bay, Florida, United States
Accel Research - Neurostudies
🇺🇸Decatur, Georgia, United States
Quest Research Institute
🇺🇸Farmington Hills, Michigan, United States
CenExel ACT
🇺🇸Anaheim, California, United States